BCM
AMLX icon

Bridgeway Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Bridgeway Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,700
Closed -$165K – 1199
2025
Q2 		$165K Sell
25,700
-130,000
-83% -$632K ﹤0.01% 998
2025
Q1 		$551K Buy
155,700
+9,200
+6% +$32.7K 0.01% 730
2024
Q4 		$554K Buy
146,500
+16,500
+13% +$77.6K 0.01% 791
2024
Q3 		$421K Hold
130,000
– – 0.01% 901
2024
Q2 		$247K Buy
+130,000
New +$252K 0.01% 1009

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bridgeway Capital Management's AMLX Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 25,700 shares — an estimated $165K sold.

Bridgeway Capital Management first reported a position in AMLX in Q2 2024 and held it in 5 quarters. The position peaked at $554K in Q4 2024. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Bridgeway Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 25,700 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $165K.
  • Bridgeway Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Bridgeway Capital Management's Amylyx Pharmaceuticals position peaked at $554K in Q4 2024.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.